Research programme: PIKFYVE inhibitors - Acurastem
Alternative Names: AS 1 - Acurastem; AS 2015; AS-1Latest Information Update: 28 Aug 2024
At a glance
- Originator AcuraStem
- Class Antidementias; Antineoplastics; Antivirals; Neuroprotectants; Small molecules
- Mechanism of Action PIKFYVE protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Frontotemporal dementia; Lymphoma; Neurodegenerative disorders; Viral infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (PO)
- 28 Aug 2023 No recent reports of development identified for research development in Lymphoma in USA
- 28 Feb 2023 No recent reports of development identified for research development in Viral-infections in USA (PO)